InterveXion met with the FDA on September 29, 2009 to discuss plans for a Phase 1 clinical trial of the PCP antibody ch-mAb6B5. InterveXion’s management team was present with its regulatory consultant from Quintiles, Dr. Raj Kishore, and members of the NIDA management group as attendees. The meeting was extremely encouraging and there were no roadblocks identified to going forward with the filing of the IND.
Recent Posts
- InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
- InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
- InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
- InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
- InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder
Archives
- October 2021
- September 2021
- April 2021
- October 2020
- May 2020
- February 2020
- January 2020
- December 2019
- November 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- February 2019
- January 2019
- December 2018
- November 2018
- May 2018
- January 2018
- October 2017
- June 2017
- January 2016
- January 2015
- November 2014
- February 2014
- August 2013
- July 2013
- December 2012
- November 2012
- May 2012
- April 2012
- July 2011
- April 2011
- October 2009
- September 2009
- March 2005
- January 2005
Recent Comments